Current joint psoriasis guidelines from the American Academy of Dermatology and the National Psoriasis Foundation emphasize the need to help patients understand the relationship between psoriasis and comorbid conditions and the importance of seeking appropriate interventions as needed.
Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.
A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.
Switching patients with moderate-to-severe plaque psoriasis from one biologic to another is a multifactorial decision and may depend on safety, efficacy or dosing intervals. Ron Vender, M.D., offers insight into how to switch appropriately.
New joint AAD-NPF guidelines consider the quality-of-life impact of pediatric psoriasis as well as comorbidity risks in this patient population.
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.
Sol-Gel announces updates to their drug pipeline and their goals for 2020, which include submitting multiple provisional patents and NDAs for the treatment of a variety of skin conditions.
A Danish study suggests that TNF inhibitors may not increase the risk of developing recurring or new primary cancers in patients with inflammatory diseases.
Ustekinumab’s short-term effect on aortic vascular inflammation points to possible role of IL-12, IL-23 in cardiovascular disease, but more research is needed.
Pediatric patients with psoriasis who experience a significant improvement in disease severity after treatment may experience the greatest positive impact to quality of life, according to a recent study.
Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
Topical halobetasol propionate 0.01% lotion appears to safely and quickly improve lower-extremity psoriatic lesions, according to a recent study.
Results from an EU phase 3 clinical trial of a combination of betamethasone dipropionate and calcipotriene cream showed improved patient convenience, quality of life and efficacy compared to a betamethasone dipropionate and calcipotriene gel for patients with plaque psoriasis.
Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.
A recent study shows promising results for using ultrasound to examine hand tendon and joint inflammation in psoriatic arthritis patients.
Researchers recently undertook an epidemiologic study to investigate the prevalence of palmoplantar pustulosis (PPP) and co-existing plaque psoriasis. Read what they discovered in this article.
Pediatric psoriasis patients may experience comorbidities, including psychiatric comorbidities, at a greater rate than children without the disease, according to a recent study.
Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.
A recent, extreme case of psoriasis demonstrates how socioeconomic factors can lead to inadequate disease control. The solution? A personalized treatment plan, says the study authors.
Psoriasis often has a greater impact on quality of life in patients with skin of color as the condition and its treatment can result in long-lasting pigmentary changes.
The 2019 joint American Academy of Dermatology and National Psoriasis Foundation phototherapy treatment of psoriasis guidelines comprehensively updates dermatologists and other providers on the state-of-the art use of various light modalities to treat psoriasis patients.
Oral health, habits and diet may influence disease severity in psoriasis, says a study published in the Dermatology Online Journal.
A study recently explored the differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders with moderate-to-severe psoriasis. Read what researchers discovered in this article.
Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.
With 4 decades of dermatology advances, we asked the very dermatologist experts who we often contact to help us to report on the milestones to weigh in on what they think have made the most difference in theirs and their patients’ lives.
